Endo gets fentanyl patch rights from Noven
Executive Summary
Transdermal drug delivery company Noven Pharmaceuticals licensed Endo Pharmaceuticals (pain management) US and Canadian rights to its transdermal fentanyl patch, currently in development to treat chronic pain.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Transdermal
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice